Taiwan Docosahexaenoic acid DHA market Size & Outlook, 2026-2034
Taiwan Docosahexaenoic acid DHA market Insights
- Based on Reed Intelligence findings, the Taiwan Docosahexaenoic acid DHA market reached USD 36.67 Million in 2025 and is estimated to attain USD 74.44 Million by 2034.
- From 2026 to 2034, the Taiwan market is expected to grow at a steady CAGR of 8.21%.
- Within the By Source category, Fish Oil dominated in 2025 in terms of market size contribution.
- Over the forecast period, Krill Oil is forecasted to deliver the fastest growth, positioning it as the most lucrative By Source segment.
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- In 2025, Taiwan accounted for 0.98% of the global Docosahexaenoic acid DHA market size.
- By 2034, United States is expected to lead the global Docosahexaenoic acid DHA market in terms of market size.
- Within Asia Pacific, China is projected to dominate the regional Docosahexaenoic acid DHA market size by 2034.
- Taiwan is identified as the fastest-growing market in Asia Pacific, anticipated to reach USD 74.6 Million by 2034.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2025 |
| Study Period | 2022-2034 |
| Historical Period | 2022-2024 |
| Forecast Period | 2026-2034 |
| Market Size In 2025 | USD 36.67 Million |
| Market Size In 2034 | USD 74.44 Million |
| Largest segment | Fish Oil |
| Units | Revenue in USD Million |
| CAGR | 8.21% (2026-2034) |
| Segmnetation Covered | |
| By Source |
|
| By Form |
|
| By Application |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
Taiwan Docosahexaenoic acid DHA market By Source 2026-2034 (USD Million)
| By Source | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fish Oil | XX.x | XX.x | XX.x | 17 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Algae Oil | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Krill Oil | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Others | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Taiwan Docosahexaenoic acid DHA market By Form 2026-2034 (USD Million)
| By Form | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Oil | XX.x | XX.x | XX.x | 16.84 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Powder | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Capsules and Softgels | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Taiwan Docosahexaenoic acid DHA market By Application 2026-2034 (USD Million)
| By Application | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Infant Formula | XX.x | XX.x | XX.x | 12.94 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Dietary Supplements | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Functional Food and Beverages | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Pharmaceuticals | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Animal Feed | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Others | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.